Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 8 records in total 8
    records per page




    COVID-19 and Guillain-Barre Syndrome MESHD - a Case report

    Authors: Amira Sidig; Khabab Abbasher; Mutaz F. Digna; Mohamed Elsayed; Hussien Abbasher; Mohammed Abbasher; Abbasher Hussien

    doi:10.21203/rs.3.rs-48327/v1 Date: 2020-07-24 Source: ResearchSquare

    Coronaviruses are a family of related viruses that cause diseases MESHD in mammals and avians. Guillain-Barre syndrome MESHD is a rare disorder in which the body's immune system attacks peripheral nerves.The case:A 65 years old Sudanese male TRANS with no diabetes mellitus MESHD diabetes mellitus HP or hypertension MESHD hypertension HP present to the clinic; On examination, he has upper and lower limb weakness ( quadriplegia MESHD). The condition was preceded by upper respiratory tract infection MESHD respiratory tract infection HP. Chest X-ray showed features of pneumonia MESHD pneumonia HP Chest CT scan showed multiple bilateral ground-glass opacities and consolidation typical of COVID-19 pneumonia MESHD pneumonia HP. Brain MRI was normal. The COVID-19 nasal swab test was positive. Nerve conduction study showed evidence of polyradiculopathies MESHD with dominant demyelination supporting the diagnosis of Guillain-Barre syndrome MESHD. The patients died after seven days; because of progressive respiratory failure HP.

    Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barre syndrome MESHD

    Authors: Stephen Keddie; Julia Pakpoor; Christina Mousele; Menelaos Pipis; Pedro M Machado; Mark Foster; Christopher J Record; Ryan Keh; Janev Fehmi; Ross W Paterson; Viraj Bharambe; Lisa Clayton; Claire Allen; Olivia Price; Jasmine Wall; Annamaria Kiss-csenki; Dipa P Rathnasabapathi; Ruth Geraldes; Tatyana Yermakova; Josh King-Robson; Maya Zosmer; Sanjeev Rajakulendran; Ross Nortley; Charles Marshall; Edward Newman; Niranjanan Nirmalananthan; Guru Kumar; Ashwin A Pinto; James Holt; Tim Lavin; Katie Brennan; Michael Zandi; Dipa L Jayaseelan; Jane Pritchard; Robert DM Hadden; Hadi Manji; Hugh J Willison; Simon Rinaldi; Aisling S Carr; Michael P Lunn

    doi:10.1101/2020.07.24.20161471 Date: 2020-07-24 Source: medRxiv

    Background Reports of Guillain-Barre Syndrome MESHD (GBS) have emerged during the Coronavirus Disease MESHD 2019 (COVID-19) pandemic. This epidemiological and cohort study sought to investigate any causative association between COVID-19 infection MESHD and GBS. Methods The epidemiology of GBS cases reported via the UK National Immunoglobulin Database were studied from 2016-2019 and compared to cases reported during the COVID-19 pandemic. For the cohort study, members of the British Peripheral Nerve Society reported all cases of GBS during the pandemic. The clinical features, investigation findings and outcomes of COVID-19 (definite or probable) and non-COVID-19 associated GBS cases were compared. Results The UK GBS incidence from 2016-2019 was 1.65-1.88 per 100,000 people per year. GBS and COVID-19 incidence varied between regions and did not correlate (r = 0.06, 95% CI -0.56 to 0.63, p=0.86). GBS incidence fell HP between March and May 2020 compared to the same months of 2016-2019. Forty-seven GBS cases were included in the cohort study (13 definite, 12 probable COVID-19 and 22 non-COVID-19). There were no significant differences in the pattern of weakness, time to nadir, neurophysiology, CSF findings or outcome. Intubation was more frequent in the COVID-19+ve cohort (7/13, 54% vs 5/22, 23% in COVID negative) thought to be related directly to COVID-19 pulmonary involvement. Conclusions This study finds no epidemiological or phenotypic clues of SARS-CoV-2 being causative of GBS. GBS incidence has fallen HP during the pandemic which may be the influence of lockdown measures reducing transmission TRANS of GBS inducing pathogens such as Campylobacter jejuni and respiratory viruses.

    Neurological manifestations associated with COVID-19: a nationwide registry

    Authors: Elodie Meppiel; Nathan Peiffer-Smadja; Alexandra Maury; Imen Bekri; Cecile Delorme; Virginie Desestret; Lucas Gorza; Geoffroy Hautecloque-Raysz; Sophie Landre; Annie Lannuzel; Solene Moulin; Peggy Perrin; Paul Petitgas; Francois Sellal; Adrien Wang; Pierre Tattevin; Thomas de Broucker; - contributors to the NeuroCOVID registry

    doi:10.1101/2020.07.15.20154260 Date: 2020-07-16 Source: medRxiv

    Background: The clinical description of the neurological manifestations in COVID-19 patients is still underway. This study aims to provide an overview of the spectrum, characteristics and outcomes of neurological manifestations associated with SARS-CoV-2 infection MESHD. Methods: We conducted a nationwide, multicentric, retrospective study during the French COVID-19 epidemic in March-April 2020. All COVID-19 patients with de novo neurological manifestations were eligible. Results: We included 222 COVID-19 patients with neurological manifestations from 46 centers throughout the country. Median age TRANS was 65 years (IQR 53-72), and 136 patients (61.3%) were male TRANS. COVID-19 was severe or critical in almost half of the patients (102, 45.2%). The most common neurological diseases MESHD were COVID-19 associated encephalopathy HP (67/222, 30.2%), acute ischemic cerebrovascular syndrome MESHD (57/222, 25.7%), encephalitis MESHD encephalitis HP (21/222, 9.5%), and Guillain-Barre Syndrome MESHD (15/222, 6.8%). Neurological manifestations appeared after first COVID-19 symptoms with a median (IQR) delay of 6 (3-8) days in COVID-19 associated encephalopathy HP, 7 (5-10) days in encephalitis MESHD encephalitis HP, 12 (7-18) days in acute ischemic cerebrovascular syndrome MESHD and 18 (15-28) days in Guillain-Barre Syndrome MESHD. Brain imaging was performed in 192 patients (86.5%), including 157 MRI (70.7%). Brain MRI of encephalitis MESHD encephalitis HP patients showed heterogeneous acute non vascular lesion in 14/21 patients (66.7%) with associated small ischemic lesion or microhemorrhages in 4 patients. Among patients with acute ischemic cerebrovascular syndrome MESHD, 13/57 (22.8%) had multi territory ischemic strokes HP strokes MESHD, with large vessel thrombosis MESHD in 16/57 (28.1%). Cerebrospinal fluid was analyzed in 97 patients (43.7%), with pleocytosis in 18 patients (18.6%). A SARS-CoV-2 PCR was performed in 75 patients and was positive only in 2 encephalitis MESHD encephalitis HP patients. Among patients with encephalitis MESHD encephalitis HP, ten out of 21 (47.6%) fully recovered, 3 of whom received corticosteroids (CS). Less common neurological manifestations included isolated seizure MESHD seizure HP (8/222, 3.6%), critical illness MESHD neuropathy (8/222, 3.6%), transient alteration of consciousness (5/222, 2.3%), intracranial hemorrhage MESHD intracranial hemorrhage HP (5/222, 2.3%), acute benign lymphocytic meningitis MESHD meningitis HP (3/222, 1.4%), cranial neuropathy (3/222, 1.4%), single acute demyelinating lesion (2/222, 0.9%), Tapia syndrome MESHD (2/222, 0.9%), cerebral venous thrombosis HP venous thrombosis MESHD (1/222, 0.5%), sudden paraparesis MESHD paraparesis HP (1/222, 0.5%), generalized myoclonus MESHD myoclonus HP and cerebellar ataxia MESHD ataxia HP (1/222, 0.5%), bilateral fibular palsy (1/222, 0.5%) and isolated neurological symptoms ( headache MESHD headache HP, anosmia HP, dizziness MESHD, sensitive or auditive symptoms, hiccups MESHD, 15/222, 6.8%). The median (IQR) follow-up of the 222 patients was 24 (17-34) days with a high short-term mortality rate (28/222, 12.6%). Conclusion: Neurological manifestations associated with COVID-19 mainly included CAE, AICS, encephalitis MESHD encephalitis HP and GBS. Clinical spectrum and outcomes were broad and heterogeneous, suggesting different underlying pathogenic processes.

    Guillain Barr e syndrome MESHD in COVID-19:A scoping review

    Authors: Imran Ahmad; Farooq Azam Rathore

    doi:10.1101/2020.06.13.20130062 Date: 2020-06-16 Source: medRxiv

    Introduction The novel coronavirus (COVID19) can result in several neurological complications. Guillain-Barre Syndrome MESHD (GBS) is one of them and has been reported from different parts of the world in this pandemic. It is an acute post-infectious polyneuropathy MESHD polyneuropathy HP. The review aims to summarize the demographic features, clinical presentation, diagnostics workup, and management strategies of COVID-19 associated GBS reported in the literature. Material and method We searched Medline, PubMed Central, SCOPUS, and Google Scholar using pre-defined keywords, with no time limits and in the English language only. We aimed to include all kinds of manuscripts. The last search was done on 18th May 2020. Demographics, clinical features, diagnostic workup, management, and outcomes were documented in the datasheet. Results We identified 24 cases of COVID-19 associated GBS. Most of the cases were reported from Italy followed by the USA. The majority were males TRANS (18 /24) The age TRANS ranged from 23 -84 years. The clinical presentation was typical sensory-motor GBS in most. Nine patients had facial palsy HP of which five had bilateral involvement. Two patients had bilateral abducent nerve palsy while two presented as paraparetic GBS variant with autonomic dysfunction. Electrodiagnostics was performed in 17 patients only and 12 had typical features of acute inflammatory demyelinating polyneuropathy MESHD polyneuropathy HP. Intravenous immunoglobulins were the preferred mode of treatment in most of the patient. There was one death MESHD, and most were discharged to rehabilitation or home. Conclusion GBS is a frequent neurological complication associated with COVID-19. There is no clear causative relationship between GBS, and COVID-19 at present, and more data are needed to establish the casualty. However, most cases have a post-infectious onset with male TRANS preponderance. Most of the cases have a typical presentation but some may present in an atypical way. Prognosis is generally good.

    Neurological Complications of COVID-19: A Systematic Review of Literature

    Authors: Shitiz Sriwastava; Samiksha Srivastava; Saurabh Kataria; Violina Melnic; Amelia Adcock; Zubeda Sheikh

    doi:10.21203/rs.3.rs-35507/v1 Date: 2020-06-14 Source: ResearchSquare

    Background: To study the nature and frequency of occurrence of “significant” neurological complications in coronavirus disease MESHD-2019 (COVID-19) via a systematic review of the literature.Methods: We screened all articles resulting from a search of PubMed, Cochrane, Google Scholar and Scopus, using the keywords "COVID-19 and CNS", "SARS-CoV-2 and CNS”, “COVID-19 and neurological manifestation”, “SARS2 and neurological manifestation” and “COVID-19 and Brain” looking for reports of significant neurological manifestations that would potentially have an impact on the outcome.Results: Twenty-six articles met the inclusion criteria. The significant neurological diagnoses reported were stroke MESHD stroke HP, Guillain Barre Syndrome MESHD (GBS) and its variants, encephalitis MESHD encephalitis HP, seizures MESHD seizures HP, acute hemorrhagic necrotizing encephalopathy, acute HP acute disseminated encephalomyelitis MESHD (ADEM) and transverse myelitis MESHD myelitis HP. Although stroke MESHD stroke HP, predominantly ischemic, was observed in ~ 6% of COVID-19 patients from Wuhan, China, mortality in this cohort was 38%. Of the 24 pooled patients with reports of etiology, 17 had large vessel occlusions. GBS occurred in 5/1200 (0.4%) of the COVID-19 cohort from Italy. One of the six reported encephalitis MESHD encephalitis HP cases, the ADEM case and the report of transverse myelitis MESHD myelitis HP do not have data for conclusive diagnosis.Conclusion: The most frequent significant neurological association with COVID-19 is stroke MESHD stroke HP, predominantly ischemic. In a cohort from Wuhan, China, this was as frequent as ~ 6%, with a 38% mortality. Most common reported etiology is large vessel occlusion. Other reported significant neurological complications are GBS/variants, encephalitis MESHD encephalitis HP, seizures MESHD seizures HP and acute hemorrhagic necrotizing encephalopathy HP. The reports of ADEM and transverse myelitis MESHD myelitis HP lacked diagnostically conclusive data.

    ACUTE VISION LOSS IN A PATIENT WITH COVID-19

    Authors: Vijairam Selvaraj; Daniel Sacchetti; Arkadiy Finn; Kwame Dapaah-Afriyie

    doi:10.1101/2020.06.03.20112540 Date: 2020-06-05 Source: medRxiv

    To date, there have been reports of neurologic manifestations MESHD in Covid-19 patients including ischemic strokes HP strokes MESHD, Guillain-Barre Syndrome MESHD and anosmia HP. In this case report, we report a patient who presented with dysosmia, dysgeusia MESHD along with monocular peripheral vision loss after being diagnosed with Covid-19.

    Neurological Involvement of Coronavirus Disease MESHD 2019: A Systematic Review

    Authors: Malik Ghannam; Qasem Alshaer; Mustafa Al-Chalabi; Lara Zakarna; Jetter Robertson; Georgios Manousakis

    doi:10.21203/rs.3.rs-31183/v1 Date: 2020-05-23 Source: ResearchSquare

    Background: In December 2019, unexplained cases of pneumonia MESHD pneumonia HP emerged in Wuhan, China, which were found to be secondary to the novel coronavirus SARS-CoV-2. On March 11, 2020, the WHO declared the Coronavirus Disease MESHD 2019 (COVID-2019) outbreak, a pandemic. Although the most common presentations of COVID-19 are fever MESHD fever HP, cough MESHD cough HP and shortness of breath, several clinical observations indicate that COVID-19 does affect the central and peripheral nervous system.  Methods: We conducted a systematic literature search from December 01, 2019 to May 14, 2020 using multiple combinations of keywords from PubMed and Ovid Medline databases according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We included articles with cases of COVID-19 that were evident for neurological involvement.  Results: We were able to identify 82 cases of COVID-19 with neurological complications. The mean age TRANS was 62.28 years. 37.8% of the patients were women (n = 31). 48.8% of the patients (n=40) had cerebrovascular insults, 28% (n=23) had neuromuscular disorders, 18.3% of the patients (n=15) had encephalitis MESHD encephalitis HP or encephalopathy HP, and 2.4% (n=2) presented with status epilepticus MESHD status epilepticus HP. Conclusions: Neurological manifestations of COVID-19 infection MESHD are not rare, especially large vessel stroke MESHD stroke HP, Guillain barre syndrome MESHD and meningoencephalitis MESHD. Moving forward, further studies are needed to clarify the prevalence SERO of the neurological complications of COVID-19, investigate their biological backgrounds, and test treatment options. Physicians should be cautious not to overlook other neurological diagnoses that can mimic COVID-19 during the pandemic.

    New clinical manifestations of COVID-19 related Guillain Barre syndrome MESHD higly responsive to intravenous immunoglobulins: two italian cases

    Authors: Andrea Assini; Luana Benedetti; Di Maio Silvia; Schirinzi Erika; Massimo Del Sette

    doi:10.21203/rs.3.rs-30354/v1 Date: 2020-05-19 Source: ResearchSquare

    Recently, some cases of Guillain Barré syndrome MESHD (GBS) and Miller Fisher (MF) have been reported, following COVID-19 infection1-2-3 . We report two different clinical manifestation of Covid-19 related GBS , one is a GBS/MF overlap syndrome MESHD, the other one an Acute Motor Sensory Axonal Neuropathy HP (AMSAN) with massive vegetative impairment, both highly responsive to intravenous immunoglobulins.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.